Skip to main content
EQL Pharma AB logo

EQL Pharma AB — Investor Relations & Filings

Ticker · EQL ISIN · SE0005497732 LEI · 549300Q8B2D2AE8GCW21 ST Manufacturing
Open in API
Filings indexed 57 across all filing types
Latest filing 2026-02-12 AGM Information
Country SE Sweden
Listing ST EQL

About EQL Pharma AB

https://eqlpharma.com/en/

EQL Pharma AB is a pharmaceutical company that develops, markets, and sells generic and specialty medicines. The company's strategy centers on identifying and developing "niche generics," which are medically equivalent to originator drugs but face limited competition after patent expiration. Its business operations also include specialty pharmaceuticals and the parallel import of medicines. EQL Pharma emphasizes cost-efficiency and collaborates with a global network of development partners. The company serves pharmacies and hospitals, primarily in the Nordic markets, maintaining a portfolio of marketed products while cultivating an extensive pipeline of new medicines.

Recent filings

Filing Released Lang Actions
Valberedning inför årsstämman 2026
AGM Information Classification · 1% confidence The document is a press release from EQL Pharma AB announcing the composition of the nomination committee (valberedning) ahead of the 2026 Annual General Meeting. It details the members of the committee and their responsibilities. Since this relates to the governance and preparation for the AGM, but is not the AGM presentation itself (AGM-R) or a proxy statement (PSI), it falls under general regulatory announcements regarding corporate governance and meeting preparation.
2026-02-12 Swedish
Nomination committee for the 2026 Annual General Meeting
AGM Information Classification · 1% confidence The document is a press release announcing the composition of the Nomination Committee for the upcoming 2026 Annual General Meeting. It outlines the committee members, their appointment process, and their responsibilities regarding the AGM. Since it is an announcement related to the preparation and governance of the AGM rather than the AGM presentation materials themselves (AGM-R) or a proxy statement (PSI), it falls under general regulatory announcements regarding corporate governance and meeting preparation.
2026-02-12 English
Bulletin from the extraordinary general meeting in EQL Pharma AB on 3 February 2026
Share Issue/Capital Change Classification · 1% confidence The document is a bulletin from an Extraordinary General Meeting (EGM) detailing the resolutions passed, specifically the implementation of a long-term incentive program involving the issuance of warrants. While it mentions a general meeting, it is not an AGM-R (Annual General Meeting) and it is not a voting results declaration (DVA) in the traditional sense of reporting vote counts; rather, it is a summary of the meeting's outcomes regarding corporate governance and incentive structures. Given the specific nature of the resolution (incentive program/warrants), it fits best under the category of regulatory announcements regarding corporate actions.
2026-02-03 English
Kommuniké från extra bolagsstämma i EQL Pharma AB den 3 februari 2026
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing the results of an Extraordinary General Meeting (extra bolagsstämma) held on February 3, 2026. It details the approval of a long-term incentive program involving the issuance of warrants. While it mentions a shareholder meeting, it is not a full proxy statement or a report of voting results (DVA), but rather a summary of the decisions made at the meeting. Given the focus on the outcome of the meeting and the specific corporate action taken, it fits best under the category of Regulatory Filings (RNS) as it is a formal announcement of corporate proceedings.
2026-02-03 Swedish
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Delårsrapport' (Interim Report) and covers the period 'April – december 2025'. It contains detailed financial tables (Nettoomsättning, Rörelseresultat, EBITDA), management commentary ('VD har ordet'), and operational updates. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2026
2026-02-03 Swedish
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim Report' and covers the period 'April – December 2025'. It contains comprehensive financial statements, including income statement data (Net sales, Gross profit, Operating profit, EBITDA), balance sheet information (Cash at end of period), and detailed management commentary on business performance, product development, and market dynamics. It is clearly a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2026
2026-02-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.